150989-59-6

Basic information

• Product Name: 8-Oxa-3-azabicyclo[5.1.0]octane-3-carboxylic acid, phenylmethyl ester
• CAS NO: 150989-59-6
• Molecular Formula: C14H17NO3
• Molecular Weight: 247.294
• Mol File: 150989-59-6.mol

Chemical Properties

• CAS DataBase Reference: 8-Oxa-3-azabicyclo[5.1.0]octane-3-carboxylic acid, phenylmethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 8-Oxa-3-azabicyclo[5.1.0]octane-3-carboxylic acid, phenylmethyl ester(150989-59-6)
• EPA Substance Registry System: 8-Oxa-3-azabicyclo[5.1.0]octane-3-carboxylic acid, phenylmethyl ester(150989-59-6)

Safety Data

• Hazardous Substances Data: 150989-59-6(Hazardous Substances Data)

Upstream product

• 5041-33-8 N-(Benzyloxycarbonyl)allylamine 
• 54436-57-6 (allyl)(pent-4-enyl)amine 
• 501-53-1 benzyl chloroformate 
• 150989-58-5 2,5,6,7-Tetrahydro-1H-azepine 
• 3349-62-0 cyclohex-2-enone oxime 
• 2228-79-7 1,5,6,7-Tetrahydro-2H-azepin-2-one 
• 281219-32-7 allylpent-4-enylcarbamic acid benzyl ester 
• 150989-62-1 2,3,4,7-tetrahydro-azepine-1-carboxylic acid benzyl ester 

Downstream Products

• 281219-34-9 4-((S)-2-tert-butoxycarbonylamino-4-methyl-pentanoylamino)-3-hydroxy-azepan-1-carboxylic acid benzyl ester 
• 281217-45-6 SB 357114 
• 281219-45-2 4(R,S)-((S)-1-{3(R,S)-hydroxy-1-[2-(3-pyridin-2-ylphenyl)ethanoyl]azepan-4-ylcarbamoyl}-3-methylbutyl)carbamic acid tert-butyl ester 
• 281219-31-6 ((S)-1-{1-[4(R,S)-((S)-2-benzyloxycarbonylamino-4-methylpentanoylamino)-3-(R,S)-hydroxyazepan-1-yl]-methanoyl}-3-methylbutyl)carbamic acid benzyl ester 
• 281214-55-9 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{(R)-3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-amide 
• 281217-40-1 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-3-methyl-1-{(S)-3-oxo-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-butyl)-amide 
• 281219-64-5 5-(2-Morpholin-4-yl-ethoxy)-benzofuran-2-carboxylic acid ((S)-1-{3-hydroxy-1-[2-(3-pyridin-2-yl-phenyl)-acetyl]-azepan-4-ylcarbamoyl}-3-methyl-butyl)-amide 
• 281219-33-8 4-azido-3-hydroxy-azepane-1-carboxylic acid benzyl ester 
• 281221-20-3 4-tert-butoxycarbonylamino-3-hydroxy-azepane-1-carboxylic acid benzyl ester 

Relevant articles and documents

M1 RECEPTOR POSITIVE ALLOSTERIC MODULATOR COMPOUNDS AND METHODS OF USE THEREOF

The present invention is directed to compounds of Formula (I): and pharmaceutically acceptable salts thereof, wherein Q, X, Y, Z, R1, R7 and n are defined herein. The compounds of Formula (I) are M1 receptor positive allosteric modul

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

AZEPANE DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS

Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.

IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING PHARMACOKINETICS OF DRUG

Imidazole derivatives of formula (I), pharmaceutically acceptable salts thereof and pharmaceutical compositions comprising at least one imidazole derivative are disclosed. The imidazole derivatives are effective to inhibit CYP450 3A and can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.

IMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG

The present invention relates to Imidazole Derivatives of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, B, Y, R1 and R2 are as defined herein. The present invention also relates to compositions comprising at least one Imidazole Derivative, and and methods of using the Imidazole Derivatives for inhibiting CYP450 3A. Inhibition of CYP450 3A can be used to improve the pharmacokinetics of a drug that is metabolized by CYP450 3A4.

COMPOUNDS FOR TREATING DISORDERS MEDIATED BY METABOTROPIC GLUTAMATE RECEPTOR 5, AND METHODS OF USE THEREOF

Provided herein are compounds and methods of synthesis thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as neurological disorders, psychiatric disorders, neuromuscular disorders, gastrointestinal disorders, lower urinary tract disorder, and cancer. Compounds provided herein modulate the activity of metabotropic glutamate receptor 5 (mGluR5) in the central nervous system or the periphery. Pharmaceutical formulations containing the compounds and their methods of use are also provided herein.

Methods of treatment

The present invention provides methods which use 4-amino-azepan-3-one protease inhibitors of cathepsin L in the treatment of diseases in which cathepsin L is implicated, especially treatment or prevention of rheumatoid arthritis; treatment or prevention of cancer metastasis; treatment or prevention of diseases requiring inhibition of tissue destruction by macrophage, particularly lung macrophage, such as asthma, chronic obstructive pulmonary disease (COPD), and emphysema; treatment or prevention of diseases requiring, for therapy, inhibition of positive selection of CD4+ T-cells by cortical thymic epithelial cells.

Cathepsin L inhibitors

The present invention provides methods which uses certain 4-amino-azepan-3-ones to inhibit cathepsin L. Consequently they are useful for preventing or treating diseases in which cathepsin L is implicated, such as rheumatoid arthritis or inhibition of posi

Protease inhibitors

The present invention provides C3-C6 1-amino-1-acyl cycloalkane-substituted 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K,

Protease inhibitors

The present invention provides 4-amino-azepan-3-one protease inhibitors and pharmaceutically acceptable salts, hydrates and solvates thereof which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, novel intermediates of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, including osteoporosis; gingival disease including gingivitis and periodontitis; arthritis, more specifically, osteoarthritis and rheumatoid arthritis; Paget's disease; hypercalcemia of malignancy; and metabolic bone disease, comprising inhibiting said bone loss or excessive cartilage or matrix degradation by administering to a patient in need thereof a compound of the present invention.